Skip to main content

Advertisement

You are viewing the new article page. Let us know what you think. Return to old version

Volume 9 Supplement 2

AIDS Vaccine 2012

Oral presentation | Open | Published:

Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C

Background

We previously demonstrated that vaccination of lactating rhesus monkeys with a DNA prime/ vector boost strategy induces strong SIV-specific cellular immune responses, but limited Envelope-specific humoral responses in breast milk. Therefore, we sought to improve vaccine-elicited Envelope-specific antibody responses in the milk compartment by using a transmitted/founder (T/F) HIV Envelope immunogen in a prime-boost strategy modeled after that of the moderately-successful RV144 HIV vaccine trial.

Methods

Eight female, hormone-induced lactating rhesus monkeys were intramuscularly primed with either recombinant DNA (n = 4) or MVA pox virus vector (n = 4) expressing the T/F clade C HIV Envelope 1086C. All animals were intramuscularly boosted twice with the 1086C gp120 protein and the adjuvant MF59. Milk, vaginal, rectal and plasma samples were assessed for HIV Envelope-binding IgG and IgA responses. Anti-V1V2 antibodies and neutralization responses were also measured in milk and plasma.

Results

Envelope 1086C-binding IgG responses were detected in plasma, milk, and vaginal samples of all vaccinated animals and two of four rectal samples from MVA-vaccinated animals. Moreover, anti-V1V2 IgG antibodies were detected in all plasma, but only one milk sample. Low magnitude Envelope 1086C-specific IgA responses were detected in milk of two of four DNA-primed and three of four MVA-primed animals, but in none of the rectal samples. In contrast, all vaginal samples from MVA-primed, but none from DNA-primed, animals had detectable Envelope-specific IgA. Remarkably, strong tier 1 and low to moderate tier 2 neutralization was detected in plasma and milk of each group. The plasma neutralization titers against MW965 (clade C tier 1, p=0.03) and CAP45 (clade C tier 2, p=0.03) were significantly higher in MVA-primed than DNA-primed animals.

Conclusion

MVA prime/ T/F Envelope protein boost strategy appears to induce stronger systemic and mucosal binding and neutralizing antibody responses than the DNA prime/protein boost regimen in lactating rhesus monkeys.

Author information

Correspondence to SR Permar.

Rights and permissions

Reprints and Permissions

About this article

Keywords

  • Neutralize Antibody Response
  • Neutralization Titer
  • Vaginal Sample
  • Plasma Neutralization
  • 1086C Gp120